Skip to content

Can Urinary Concentrations of TIMP2 and IGFBP7 be Used to Predict Early Acute Renal Failure Following Cardiac Arrest?

Can Urinary Concentrations of TIMP2 and IGFBP7 be Used to Predict Early Acute Renal Failure Following Cardiac Arrest?

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03211962
Acronym
ACR-CHECK
Enrollment
77
Registered
2017-07-11
Start date
2017-02-01
Completion date
2019-03-01
Last updated
2020-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Renal Failure

Brief summary

Transient renal insufficiency is frequently observed in the course of cardiovascular arrest. Although elevation of creatinine is reversible in a large majority of cases, severe renal insufficiency is sometimes observed and is associated with a dark prognosis. Any intervention that may limit the worsening of renal function may have an impact on patient mortality. There is currently no validated pharmacological treatment to limit the progression of ARI or to accelerate its recovery. A major challenge then concerns the detection of the reversible character of renal damage. Renal biomarkers have been little studied in the prediction of severe ARI and mortality after cardiac arrest. The combination of TIMP2 (tissue inhibitor of metalloproteinase) and insulin-like growth factor binding protein (IGFBP7) in urine showed good diagnostic performance in the early detection of the risk of developing acute renal failure within 12 hours. Measured in the urine, the excretion of these two markers specifically reflects renal tubular lesions. Moreover, their rate seems to be strongly correlated with the severity of the tubular lesions. Thus, it can be reasonably assumed that their very early dosing in post-cardiac arrest could detect the presence and severity of renal tubular lesions. A threshold to be defined would discriminate patients at risk of developing an ARI within 48 hours post ACR and to distinguish between severe transient and severe persistent lesions beyond 72 hours.

Interventions

OTHERAnalysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest

Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest

Sponsors

Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age over 18 years * Cardio-circulatory arrest within 6 hours * Person affiliated to a social security scheme

Exclusion criteria

* Acute renal failure requiring urgent ERA in the opinion of the resuscitator Anuria * Chronic renal insufficiency stage 4-5 with a glomerular filtration rate estimated at less than 30 ml / min. * Rapidly progressive renal disease (glomerulonephritis, HUS, obstruction ...) Renal Insufficiency * Probable glomerular involvement (nephritic syndrome, nephrotic syndrome, chronic glomerulonephritis) * Pregnant or nursing women * Patient under tutelage or curatorship or deprived of public right. * Transplantation * Subject involved in another search including an exclusion period still in progress at pre-inclusion

Design outcomes

Primary

MeasureTime frame
Analysis of the predictive value of the urinary concentration of TIMP2-IGFBP7Analysis of the predictive value of the urinary concentration of TIMP2-IGFBP7 in the development of acute renal insufficiency defined by the KDIGO 3 stage within 48 hours after inclusion

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026